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Abstract
The screening of groups with a high risk for developing tu-
berculosis (TB) is a priority in order to control this disease. 
Since there is no gold standard for the diagnosis of latent TB 
infection (LTBI), both the tuberculin skin test (TST) and the 
interferon-gamma release assays (IGRA) have been used for 
this purpose. The aim of this study was to determine the pro-
portion of LTBI by using the TST and the IGRA tests, and to 
assess the risk factors related with discordant results be-
tween tests across several risk groups advised for screening 
in Northeast Portugal. Data were collected from the data-
base of patients with suspected LTBI and advised for the 
screening in a public health unit (January 2014 to December 
2015). The proportion of LTBI was computed using both 
tests. Logistic regression models assessed risk factors for a 
positive test and for discordant results between tests. The 
adjusted odds ratio (OR) and respective 95% confidence in-
terval (95% CI) were obtained. Out of 367 patients included 
in the analysis, 79.8% had a positive TST and 46.0% of them 
had a positive IGRA. In comparison with contacts of active TB 
cases, healthcare workers and inmates presented higher 
odds of TST positivity (OR 4.38, 95% CI 1.59–12.09 and OR 
4.74, 95% CI 1.45–15.49, respectively), but immunocompro-
mised people presented lower odds of TST positivity (OR 
0.14; 95% CI 0.06–0.31). Instead, healthcare workers (OR 0.44, 
95% CI 0.24–0.80) and immunocompromised people (OR 
0.24, 95% CI 0.10–0.56) presented lower odds of a positive 
IGRA. There were 42.0% concordant positive results, 16.1% 
concordant negative results, and 41.9% discordant results, 
with healthcare workers presenting higher odds of discor-
dant results (OR 3.34, 95% CI 1.84–6.05). The proportion of 
LTBI estimated by TST and IGRA among people advised for 
screening in our setting is high, highlighting the need of pre-
ventive strategies. Among healthcare workers, TST results 
should be read with caution as the higher proportion of dis-
cordant results with a positive TST suggests the impact of 
the booster reaction in this group.
© 2021 The Author(s). Published by S. Karger AG, Basel 
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Teste Intradérmico da Tuberculina versus Teste 
de Deteção de Interferão-Gama numa Unidade de 
Saúde no Nordeste de Portugal
Palavras Chave
Tuberculose · Infeção Tuberculosa Latente · Teste 
Intradérmico à Tuberculina · Teste de Deteção de 
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Resumo
O rastreio de grupos de risco para o desenvolvimento de 
tuberculose (TB) é uma prioridade para o controlo da doen-
ça. Uma vez que não existe um “gold-standard” para o diag-
nóstico de infeção latente (ITBL), o teste intradérmico da 
tuberculina (TST) e o teste de deteção de interferão-gama 
(IGRA) têm sido usados com esse propósito. O objetivo 
deste estudo foi determinar a proporção de ILTB através do 
TST e do teste IGRA e avaliar os fatores associados à dis-
cordância de resultados entre testes, considerando vários 
grupos de risco aconselhados para rastreio no Nordeste de 
Portugal. Os dados foram obtidos da base de dados de 
utentes de uma unidade local de saúde com suspeita de 
ILTB e orientados para rastreio (janeiro de 2014 a dezembro 
de 2015). Foi obtida a proporção de ILTB usando ambos os 
testes. Os modelos de regressão logística avaliaram os fa-
tores de risco para um teste positivo e para resultados dis-
cordantes entre os testes. Obtiveram-se as estimativas de 
odds ratio (OR) e o respetivo intervalo de confiança de 95% 
(IC95%). Dos 367 pacientes incluídos na análise, 79,8% ti-
veram um TST positivo e 46,0% deles tiveram um IGRA pos-
itivo. Em comparação com contatos de casos de TB ativa, o 
risco de TST positivo foi maior em profissionais de saúde e 
presidiários (OR = 4.38; 95% CI: 1.59–12.09 e OR = 4.74 95% 
CI: 1.45–15.49, respetivamente) e menor em imunocom-
prometidos (OR = 0.14; 95% CI: 0.06–0.31). Por outro lado, 
os profissionais de saúde (OR = 0.44; 95% CI: 0.24–0.80) e 
imunocomprometidos (OR = 0.24; IC95%: 0.10–0.56) apre-
sentaram menor risco de IGRA positivo. Houve 42.0% de 
resultados positivos concordantes, 16.1% de negativos 
concordantes e 41.9% de discordantes, com os profission-
ais de saúde a apresentarem maior risco de resultados dis-
cordantes (OR = 3.34; 95% CI: 1.84–6.05). A proporção de 
ILTB estimada pelo TST e IGRA nestes utentes aconselhados 
a fazer rastreio revelou-se alta, evidenciando a necessidade 
de estratégias preventivas. Entre os profissionais de saúde, 
os resultados do TST devem ser lidos com cautela, pois a 
maior proporção de resultados discordantes com um TST 
positivo sugere o impacto do efeito booster neste grupo. 
© 2021 The Author(s) Published by S. Karger AG, Basel
Introduction
Tuberculosis (TB) results from Mycobacterium tuber-
culosis infection, which infects almost a quarter of the 
world’s population and remains an important cause of ill 
health and mortality worldwide [1]. Over 90% of infected 
individuals remain asymptomatic and are not infectious 
due to the persistent immune response to M. tuberculosis 
that persists within the human host as latent TB infection 
(LTBI). People with LTBI are at risk of developing active 
TB disease and becoming infectious during their lifetime, 
leading to death if left untreated [2]. Specific groups of 
people have a high risk of developing TB, including con-
tacts of TB cases [3–5], HIV-positive people [6], health-
care workers (HCW) [6, 7], immigrants from countries 
with a high TB burden [3], immunocompromised pa-
tients [6], prisoners, homeless people, and illicit drug us-
ers [8].
The prophylaxis of individuals with LTBI is a strategy 
to control active TB, but there are no accurate methods to 
identify these individuals [1]. Diagnosis of LTBI relies on 
the measurement of host immune responses to M. tuber-
culosis antigens which are based on a specific immune 
response against the bacillus, by using the tuberculin skin 
test (TST) or interferon-gamma (IFN-γ) release assays 
(IGRA) [2, 9–11]. The TST measures the delayed-type hy-
persensitivity response to intradermal injection of puri-
fied protein derivative, a crude mixture of several myco-
bacterial antigens which are common to M. tuberculosis, 
M. bovis BCG, and non-tuberculous mycobacteria (NTM) 
[10]. In turn, IGRA is an in vitro blood test, detecting the 
release of IFN-γ by circulating T-lymphocytes in response 
to epitopes from specific M. tuberculosis complex-associ-
ated antigens, namely ESAT-6 and CFP-10 [2, 11]. The 
TST is a simple and cost-effective test, but it needs a fol-
low-up visit for result interpretation [10, 11], while IGRA 
requires blood samples and a laboratory to process them 
quickly after collection [11].
There is a body of research on comparing the perfor-
mance of TST and IGRA in the general population [12] 
and in specific population subgroups such as children, 
immunocompromised people, those from countries 
with high TB rates [13], contacts of active TB cases [4, 
14, 15], homeless people, refugees, HIV-positive cases 
[16], and HCW [14, 17–22]. There are no consistent re-
sults across studies and such variability could be ex-
plained by differences in demographic characteristics 
[16, 20], the community TB burden [4, 13], the immune 
status [13], or the prevalence of the BCG vaccination 
[16, 20].
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Although the TB incidence rate in Portugal has been 
decreasing, it remains one of the highest TB rates in Eu-
rope [23], demanding effective identification and treat-
ment of individuals with LTBI. As far as we know, the 
performance of TST and IGRA for diagnosing LTBI in 
the Portuguese population was limited to the screen of 
HCW [21, 22]. Thus, we aimed to determine the propor-
tion of LTBI by using the TST and the IGRA test and to 
assess the risk factors related with discordant results be-
tween tests across several risk groups advised for screen-
ing in Northeast Portugal.
Materials and Methods
This study was carried out in a public health unit in the North-
east Portugal. Data were collected from the database of patients 
with suspected LTBI and advised for screening. In our setting it is 
mandatory to fill in a questionnaire asking for relevant informa-
tion before patients undergo screening tests for LTBI. The ques-
tionnaire asks for the following information: age, gender, BCG 
vaccination status, HIV/SIDA diagnosis, and the reason for the 
suspected LTBI. All 377 patients screened between January 2014 
and December 2015 who underwent both TST and IGRA were 
considered eligible participants. After excluding 3 (0.8%) patients 
with indeterminate IGRA and 7 (1.9%) patients due to a diagnosis 
of active TB, 367 participants were included in the present analysis.
TST and IGRA
Blood was collected for the IGRA and analyzed with the Quan-
tiFERON Gold In-Tube assay (Cellestis/Qiagen, Dusseldorf, Ger-
many). The IGRA method quantifies the IFN-γ released after the 
incubation of blood with a cocktail of peptides derived from ESAT-
6, CFP-10, and TB7.7 (Rv2654c) antigens [24]. The IGRA was con-
sidered positive if the level of IFN-γ was 0.35 IU/mL or more [24].
The TST was performed by using an intradermal injection of 
5 U of tuberculin (Pasteur Institute, Paris, France) on the volar side 
of the forearm. The transverse diameter of induration was read 
72 h later [25]. Following recent guidelines, the TST was consid-
ered positive if the diameter of induration had 5 mm or more 
among children aged less than 5 years old, immunocompromised 
people, and those with a diagnosis of HIV/SIDA [26]. 
Potential Predictors
The following variables were considered potential predictors of 
TST or IGRA positivity and were retrieved from the database: gen-
der, age, BCG immunization, HIV status and risk group for TB 
Table 1. Predictors of positive IGRA or positive TST
Total Positive TST OR1 (95% CI) Positive IGRA OR2 (95% CI)
Age, years 43.8±15.94 44.6±15.25 1.03 (1.00–1.05) 46.8±16.16 1.02 (1.00–1.03)
p = 0.174 p = 0.001
Gender Female 183 146 (79.8) 1 78 (42.6) 1
Male 184 147 (79.9) 0.78 (0.42–1.47) 91 (49.5) 0.80 (0.47–1.36)
p = 0.979 p = 0.227
BCG 
immunization
No 43 32 (74.4) 1 25 (58.1) 1
Yes 152 117 (77.0) 0.99 (0.37–2.63) 50 (32.9) 0.34 (0.15–0.76)
Unknown 172 144 (83.7) 94 (54.7)
p = 0.728 p = 0.005
HIV status Negative 298 241 (80.9) 1 144 (48.3) 1
Positive 5 4 (80.0) 0.32 (0.02–4.54) 3 (60.0) 0.56 (0.07–4.57)
Unknown 64 48 (75.0) 22 (34.4)
p = 0.961 p = 0.947
Risk groups 
for TB
Contacts of active TB cases 157 122 (77.7) 1 83 (52.9) 1
HCW 86 81 (94.2) 4.38 (1.59–12.09) 29 (33.7) 0.44 (0.24–0.80)
Inmates 58 54 (93.1) 4.74 (1.45–15.49) 35 (60.3) 1.35 (0.66–2.77)
Immunodepression 37 15 (40.5) 0.14 (0.06–0.31) 10 (27.0) 0.24 (0.10–0.56)
Other 29 21 (72.4) 0.79 (0.31 – 2.00) 12 (41.4) 0.74 (0.32–1.74)
p < 0.001 p = 0.001
Data are presented as the mean ± SD or n (%). p corresponds to the p value for bivariate analysis comparing positive and negative 
results. TB, tuberculosis; HCW, healthcare workers.
1 Adjusted for all other variables in the table; Hosmer-Lemeshow goodness-of-fit test p value = 0.416. 
2 Adjusted for all other variables in the table; Hosmer-Lemeshow goodness-of-fit test p value = 0.809. 
Afonso/Pires/Teixeira/NogueiraPort J Public Health 2020;38:159–165162
DOI: 10.1159/000514875
(contacts of active TB, HCW, inmates, immunodepression status, 
and other circumstances). 
Statistical Analysis
Participants were classified as LTBI positive or LTBI negative 
for each test (TST and IGRA) and were categorized into four 
groups: negative for both tests (TST–/IGRA–), positive for both 
tests (TST+/IGRA+), discordant with positive TST (TST+/IGRA–), 
and discordant with positive IGRA (TST–/IGRA+). The propor-
tion of positive TST (≥5 mm for children aged less than 5 years, 
immunocompromised people, and those with a diagnosis of HIV/
SIDA or ≥10 mm for other people) or positive IGRA (≥0.35 IU/
mL), concordant positive, concordant negative, and discordant 
tests were computed. Bivariate analysis was performed to compare 
groups according to the TST and IGRA results. Multivariate logis-
tic regression analysis was performed to evaluate the association 
between a positive TST, a positive IGRA, or a discordant result as 
dependent variables, and the age, gender, HIV status, BCG immu-
nization status, and the risk group of the patients as potential pre-
dictors of LTBI proportion. Estimates of odds ratio (OR) adjusted 
for all these potential predictors and the respective 95% confidence 
interval (95% CI) were obtained. Analyses were performed using 
the SPSS statistical software for Windows (SPSS version 26.0). The 
general significance level was set to 0.05.
Results
A total of 367 individuals were included in this analy-
sis; 42.7% (n = 157) were contacts of active TB cases, 
23.4% (n = 86) were HCW, 15.8% (n = 58) were inmates, 
10.1% (n = 37) were immunosuppressed people, and 7.9% 
(n = 29) corresponded to other risk groups. Out of all of 
the participants, 79.8% (n = 293) had a positive TST and 
46.0% (n = 169) of them had a positive IGRA.
Table 1 presents the proportion of positive TST or 
positive IGRA. According to the bivariate analysis, the 
proportion of positive TST was significantly different 
across risk groups for TB (p < 0.001), varying from 
40.5% (immunocompromised people) to 94.2% (HCW). 
The proportion of IGRA positivity was significantly dif-
ferent between groups by BCG immunization (p = 
0.005), varying from 32.9% (vaccinated) to 58.1% (non-
vaccinated), and across risk groups for TB (p = 0.001), 
varying between 27.0% (immunocompromised people) 
and 60.3% (inmates). After adjustment for all other 
variables, older people were more likely to present TST 
positivity (OR 1.03, 95% CI 1.01–1.05) or IGRA positiv-
ity (OR 1.02, 95% CI 1.00–1.03). Compared with TB 
contacts, the odds of TST positivity was higher among 
HCW and inmates (OR 4.38, 95% CI 1.59–12.09 and 
OR 4.74, 95% CI 1.45–15.49, respectively) but lower 
among immunocompromised subjects (OR 0.14, 95% 
CI 0.06–0.31). The odds of IGRA positivity were lower 
among BCG-vaccinated people (OR 0.34, 95% CI 0.15–
0.76) compared with non-vaccinated people. When 
compared with TB contacts, HCW and immunocom-
promised people presented lower odds of a positive 













Age, years 40.4±17.91 44.7±15.77 42.2±19.65 41.6±14.13 0.009 1.00 (0.98–1.01)
Gender Female 32 (17.5) 73 (39.9) 5 (2.7) 73 (39.9) 0.414 1
Male 27 (14.7) 81 (44.0) 10 (5.4) 66 (35.9) 1.31 (0.77–2.21
BCG 
immunization
No 7 (16.3) 21 (48.8) 4 (9.3) 11 (25.6) 0.019 1
Yes 29 (19.1) 44 (28.9) 6 (3.9) 73 (48.0) 1.77 (0.80–3.93)
HIV status Negative 43 (14.4) 130 (43.6) 14 (5.0) 111 (36.6) 0.792 1
Positive 1 (20.0) 3 (60.0) 0 (0.0) 1 (20.0) 0.55 (0.06–5.57)
Risk groups 
for TB
Contacts of active TB cases 27 (17.2) 75 (47.8) 8 (5.1) 47 (29.9) <0.001 1
HCW 5 (5.8) 29 (33.7) 0 (0.0) 52 (60.5) 3.34 (1.84–6.05)
Inmates 2 (3.4) 33 (56.9) 2 (3.4) 21 (36.2) 1.39 (0.68–2.84)
Immunodepression 19 (51.4) 7 (18.9) 3 (8.1) 8 (21.6) 0.89 (0.39–2.03)
Other 6 (20.7) 10 (34.5) 2 (6.9) 11 (37.9) 1.53 (0.67–3.52)
Data are presented as the mean ± SD or n (%). TB, tuberculosis; HCW, healthcare workers. 
1 Bivariate analysis. 
2 Adjusted for all other variables; Hosmer-Lemeshow Goodness-of-fit test p value = 0.931.
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IGRA (OR 0.44, 95% CI 0.24–0.80 and OR 0.24, 95% CI 
0.10–0.56, respectively).
Table 2 shows the proportion of discordant and con-
cordant results by groups according to the potential pre-
dictors. There were 42.0% (n = 154) TST+/IGRA+, 16.1% 
(n = 59) TST–/IGRA–, 4.1% (n = 15) TST–/IGRA+, and 
37.9% (n = 139) TST+/IGRA–. According to the bivariate 
analysis, some variables presented a significant associa-
tion with discordant results, namely age (p = 0.009), BCG 
immunization (p = 0.019), and the risk groups for TB 
(p < 0.001). However, after adjustment for all other vari-
ables, only risk groups for TB were related with a discor-
dant result; compared with TB contacts, HCW had 3-fold 
higher odds of a discordant result (OR 3.34, 95% CI 1.84–
6.05).
Discussion
This is the first study conducted in Northeast Portugal 
on the proportion of LTBI, for which purpose we used 
TST and IGRA. According to our results, the proportion 
of LTBI estimated by IGRA and TST was 46 and 80%, re-
spectively. Among HCW, the proportion of positive 
IGRA was 34%, similar to data reported in previous re-
search conducted in Portugal [21]. However, according 
to a recent systematic review, the prevalence of LTBI 
among HCW by using IGRA in low-incidence countries 
was only 16% [27]. Also, the proportion of LTBI we found 
among TB contacts and inmates was higher than reported 
in other European settings [4, 14, 28, 29]. Our findings 
probably reflect the TB burden in Portugal, a country 
with one of the highest incidence rates (20.5 new cases 
and relapses of TB per 100,000 population) and with one 
of the lowest TB treatment success rates (37.3%) among 
European countries in 2018 [23]. 
Previous research has reported the association be-
tween positive results with TST or IGRA and several pre-
dictors of TB [5, 12, 15, 17–20], but there are no consis-
tent results across studies. We found an association be-
tween age and positive results with both tests, with older 
people presenting a higher risk of a positive test, in accor-
dance with some previous studies [12, 15]. However, in 
other studies, age was related only with IGRA results [14, 
18] or no association existed between age and positivity, 
either with TST or IGRA [5, 19, 20]. 
We found no association between BCG immunization 
and TST positivity. Interestingly, IGRA positivity was less 
likely among immunized people, in accordance with pre-
vious research suggesting the relevance of the IGRA 
screening test in LTBI evaluation [12, 19]. The higher 
specificity of IGRA to detect M. tuberculosis infection 
[29] and the protective effect of BCG vaccination on M. 
tuberculosis infection [12] could explain our results.
Despite the lack of a gold standard to diagnose LTBI, 
we compared IGRA with TST results for estimate the pro-
portion of LTBI among people with suspected LTBI and 
advised for screening. Our findings showed a low rate of 
TST–/IGRA– (16.1%), while the rate of TST+/IGRA+ 
reached 42.0%. Previous research enrolling TB contacts 
and HCW [14, 17, 19] reported a lower rate of TST+/
IGRA+ and higher rate of TST–/IGRA– than we found. 
In some settings the diagnosis of LTBI is only considered 
when both tests are positive [3]; therefore, our results sug-
gest a high risk of LTBI among people advised for the 
screening in our setting, demanding preventive strategies 
against TB. 
The proportion of LTBI we found was higher when us-
ing TST than when using IGRA, which leads to a higher 
proportion of TST+/IGRA– among discordant results, 
and these findings are in accordance with previous re-
search [14, 17, 19, 20]. However, our rate of discordant 
results (41.9%) was higher, particularly among HCW 
(61%), than reported in previous research [14, 17, 19]. 
According to our results, in comparison with TB con-
tacts, HCW presented a higher proportion of TST posi-
tivity but lower proportion of IGRA positivity. It has been 
reported that IGRAs provide higher specificity than the 
TST [30]. The TST is more sensitive than IGRA [2, 11, 30] 
as a positive TST may be due to BCG vaccination or ex-
posure to environmental NTM [2, 11]. According to our 
results, BCG vaccination did not explain discordant re-
sults after adjusting for the other variables, indicating the 
impact of other factors, rather than BCG vaccination, in 
explaining discordant results. Indeed, only HCW re-
mains a predictor of discordant results, and the discor-
dant results in this group are TST+/IGRA–. Repeated 
TST as a surveillance strategy among HCW could boost 
the TST reaction among those with a previous M. tuber-
culosis or NTM infection [31, 32], similar to what has 
been observed among BCG-vaccinated people [32]. It is 
not clear whether these results could be explained by the 
exposure to NTM [2], as NTM infections appear respon-
sible for positive TSTs among HCW [31].
Based on WHO recommendations, either TST or 
IGRA can be used to evaluated LTBI, because no strong 
evidence suggests that one test should be preferred over 
the other for predicting progression to active TB disease 
[8]. However, the TST and IGRA results we observed 
across risk groups suggest the need for caution in reading 
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the TST, as it seems be affected by other factors rather 
than recent exposure to M. tuberculosis. 
The current study gives insights concerning the pro-
portion of LTBI in several risk groups for TB by including 
all individuals with suspected LTBI in a specific commu-
nity in Northeast Portugal who were advised for the 
screening. Nevertheless, there are some limitations. As we 
used the data from a single public health unit, we should 
be cautious in generalizing the findings. Furthermore, we 
missed some details. We have no information about the 
number of years in the healthcare profession, level of oc-
cupational risk or job category, and the time of exposure 
to M. tuberculosis, which have been reported to be associ-
ated with LTBI [4, 17, 33].
Conclusion
The proportion of LTBI estimated by TST and IGRA 
is high among people advised for LTBI screening in 
Northeast Portugal, highlighting the need for strategies to 
control TB. The interpretation of TST results requires 
caution, particularly among HCW, due to a higher pro-
portion of TST+/IGRA–, suggesting the impact of the 
booster reaction to previous M. tuberculosis exposure. 
Further research is needed by including more detailed in-
formation about participants.
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